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Background: Cystic fibrosis (CF) is characterized by chronic inflammation with increased oxidative stress. We evaluated the relationship between
glucose tolerance and oxidative stress in CF children.
Methods: Patients 10–18 years old underwent oral glucose tolerance testing (n=31). At 2-h, we assessed blood glutathione and 4-hydroxynonenal-
protein adducts (HNE-P), and urine 1,4-dihydroxynonane-mercapturic acid conjugate (DHN-MA). Plasma fatty acid (FA) profile was performed.
Patients with impaired glucose tolerance (IGT) were retested 6 to 24 months later and received additional nutritional recommendations (NR) when
possible.
Results: Fifty-two percent of patients had normal glucose tolerance (NGT), 42% IGT and 6% cystic fibrosis-related diabetes (CFRD). HNE-P
concentrations significantly increasedwith diabetes (109%). Two-hBGcorrelated positivelywithHNE-P and negativelywithDHN-MA. FAprofile was
modified with IGT. Of retested IGT patients, 25% received no NR; they remained IGTat 6 months and progressed to CFRD. Of those who receivedNR,
67% normalized, 11% remained intolerant and 22% developed CFRD. HNE-P levels dropped (88%) in IGT patients reverting to NGT, increased (94%)
in the IGT patients with NR developing CFRD, decreased (90%) with persistent IGT.
Conclusion: CF children showed evidence of increased oxidative stress with worsening of glucose metabolism. NR may delay the appearance of
CFRD.
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Cystic fibrosis (CF), themost common lethal genetic disease in
Caucasians [1], is caused by mutations of a gene encoding the
cystic fibrosis transmembrane conductance regulator (CFTR).
The most frequent mutation is the deletion of a phenylalanine
residue at position 508 (ΔF508). The CFTR protein, a chloride
channel, is also involved in homeostasis of other ions and
metabolites such as glutathione [2]. In CF, the defective water and
chloride transport leads to viscous secretions causing scarring and
destruction of organs. This may result in exocrine and endocrine
pancreatic insufficiency as well as cystic fibrosis-related diabetesd by Elsevier B.V. All rights reserved.
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prevalence of treatment-requiring diabetes of 17% in females and
12% in males aged ≥13 years [3].
The pathophysiology of abnormal glucose metabolism in CF
patients is multifactorial. Endocrine pancreatic dysfunction may
be due to impairment of β-cell function with progressive
fibrosis of Langherans islets, resulting in distortion, ischemia,
cell death, a decrease in number of islets and disturbances of
other islet cell functions. Other contributory factors may include
defects in insulinotropic gut hormone secretion and changes in
insulin sensitivity and clearance rate [4–7]. Islet cell antibodies,
the ΔF508 genotype and hepatic as well as peripheral insulin
resistance may also be involved [8,9].
Oxidative stress has been implicated in the pathophysiology
of several chronic diseases. CF is characterized by chronic
inflammation with increased oxidative stress and glutathione
imbalance [10,11], possibly by abnormal glutathione transport
across the CFTR. The resulting glutathione deficiency has been
associated with changes in other antioxidant levels, increased
oxidative stress with hepatic and pancreatic damage, increased
lipid peroxidation, and enhanced protein oxidation, denatura-
tion and aggregation [12–15]. However, this systemic glu-
tathione deficiency is not related to defects in glutathione
synthesis nor in the transferase, redox or recycling systems [11].
Evaluation of oxidative stress requires accurate quantifica-
tion of secondary products such as isoprostanes, aldehydes and
oxidized proteins [16]. Furthermore, polyunsaturated fatty
acids (PUFA) are major targets of free radical attacks leading to
lipid peroxidation and production of several toxic metabolites
[17]. Compared to isoprostanes, the longer half-life of alde-
hydes makes them good candidates for propagation and
amplification of effects elicited by free radicals. Amongst
aldehydes, the 4-hydroxy-2-alkenals, including 4-hydroxyno-
nenal (HNE), a normal constituent of mammalian cell
membranes, are considered the most reactive species. HNE
reacts with thiol and amino residues of proteins, peptides, lipids
and nucleic acids [18]. Accumulation of modified proteins,
particularly HNE-protein adducts, depends on the degree of
insult and can lead to increased production of reactive oxygen
species (ROS). Growing evidence supporting HNE's role as a
(patho)physiological modulator of signal transduction, tran-
scriptional regulation and protein activities, targets HNE in the
development and progression of diseases [19]. In diabetes, the
production of reactive oxygen and nitrogen species appears to
be a consequence of hyperglycemia, the effects of which are
partly mediated through increased protein glycation and oxi-
dation [20]. Molecular rearrangements occurring in such
reactions result in the formation of more ROS [21], which
can decrease antioxidant capacity and activate redox-sensitive
transcription factors [22]. Moreover, the evaluation of in vivo
HNE metabolism has been shown to be possible with the HNE
urinary end-product, 1,4-dihydroxynonane-mercapturic acid
adduct (DHN-MA) [23,24].
Abnormal fatty acid composition and metabolism have been
associated with the development of CF. It has been estimated
that an essential fatty acid deficiency (EFAD) occurs in up to
85% of CF patients [25], characterized by increased plasmalevels of oleic (C18:1n-9) and palmitoleic (C16:1n-7) acids
[26,27] and low levels of arachidonic (C20:4n-6; AA), linoleic
(C18:2n-6; LA) and docosahexaenoic (C22:6n-3; DHA) acids
[28]. In CF, EFAD is clinically more severe in infants and may
occur even before the condition is diagnosed [29]. Although
many factors related to fat malabsorption [30] or altered
utilisation of fatty acids in cells [31] can explain the
modification in the fatty acid profile, peroxidation of PUFA
[32,33] seems to be more relevant.
Given that increased oxidative stress has been implicated in
the progression of both CF and diabetes, this raises the
possibility of its involvement in the development of CFRD.
Our goals were as follows: 1) To evaluate glucose metabolism
in CF patients from 2 pediatric centers, 2) To determine whether
markers of oxidative stress, such as glutathione, HNE-P adducts
and DHN-MA, are correlated to and possibly predictive of
glucose metabolism in CF patients, and 3) To evaluate whether
plasma FA profiles are related to markers of oxidative stress or
glucose tolerance in CF.
2. Methods
2.1. Patients
Patients were recruited through the pediatric CF clinics at the
CHU Sainte-Justine and the Montreal Children's Hospital.
Informed consent was obtained after institutional review board
approval. Inclusion criteria were a documented diagnosis of CF,
age N10 years, previously normal glucose metabolism and
follow-up by a collaborating physician. Patients taking
medications known to interfere with glucose metabolism and
those with psychological problems, acute illness or other
ongoing medical problems were excluded. During the recruit-
ment period (2 months), 2 patients attending the clinics refused
to participate. Two patients had CFRD and a comparable
number of patients for normal and impaired glucose intolerance
were included: 16 and 13 for NGT and IGT respectively, for a
total of 31 patients.
2.2. Oral glucose tolerance test (OGTT)
After an overnight fast, patients underwent oral glucose
tolerance testing using 1.75 g/kg (maximum 75 g) of dextrose
solution. Blood was taken at time 0 (fasting) for evaluation of
glucose, insulin and A1c, and at 2 h for glucose, insulin and
oxidative stress markers. Glucose tolerance was classified
according to the Canadian Diabetes Association guidelines [34].
Patients with CFRD were referred to an endocrinologist. At the
CHU Sainte-Justine, IGT patients received additional nutri-
tional recommendations (NR) from a dietician to avoid simple
concentrated sugars and high glycemic index foods. All IGT
patients underwent repeat OGTT after 6 to 24 months.
2.3. Pulmonary function
Pulmonary function was assessed using forced expiratory
volume in one second (FEV1) and forced expiratory flow25–75
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2.4. Pseudomonas aeruginosa
Sputum cultures were performed to identify Pseudomonas
aeruginosa (PA) colonization at the time of the OGTT.
2.5. Analyses of oxidative stress
To avoid measurement bias, 2-h samples were coded and
glucose tolerance status was revealed after analyses were
completed.
2.5.1. Glutathione assay
Oxidized glutathione (GSSG) and total glutathione (GSH+
GSSG) measurements were assessed by a spectrophotometric
method using vinylpyridine as described [35] in aliquots
(500 µl) of whole blood (heparinized tubes). Reduced glu-
tathione (GSH) concentration was calculated as the difference
between total and oxidized glutathione.
2.5.2. HNE-protein adducts assay
Chemicals and organic solvents were supplied by Laboratoire
Mat (Montreal, QC, Canada), Sigma Chemical Co. (St. Louis,
MO, USA) and J.T. Baker (Phillipsburg, NJ, USA). Biomol
(Plymouth Meeting, PA, USA) provided unlabeled HNE while
Regis Chemical (Morton Grove, IL, USA) supplied N-methyl-N-
(t-butyldimethylsilyl)-trifluoroacetamide. NaB2H4 and trans-4-
hydroxy-2-nonenal-[5,5,6,6,7,7,8,8,9,9,9-2H11]diethyl acetal
were purchased from Cambridge Isotope Laboratories (Andover,
MA, USA) and CDN Isotopes (Pointe-Claire, QC, Canada),
respectively. Quantification of HNE bound to proteins in whole
blood samples (400 µl, EDTA tubes) [36] was assessed as
follows: After addition of 200 µl of NaB2H4 (1M) reducing HNE
to its corresponding alcohol chemically stable [2H]DHN, proteins
were precipitated with saturated sulfosalicylic acid (200 µl). The
protein pellet was extracted twice with mixed methanol:chloro-
form (3 ml; 2:1, vol:vol), rinsed thrice with water (1 ml) before
resuspension in guanidine buffer (0.5 ml; pH 7.2) and addition of
internal standard [2H11]1,4-dihydroxynonene (DHN; 0.1 nmol).
After treatment with Raney Nickel, extraction and evaporation,
the residue was treated with N-methyl-N-(t-butyldimethylsilyl)-
trifluoroacetamide (75 µl), heated (90 °C, 3 h) and left overnight
(70 °C) for derivatization.
Two μl aliquots were injected into a Hewlett Packard 6890
Series GC System version A.02.14 (Hewlett Packard, Palo
Alto, CA, USA) equipped with HP-5 capillary column
(50 m×0.2 mm×0.33 µm) coupled to a Mass Spectrometer
(Agilent Technologies Mass Selective Detector 5973 Network)
operated in ammonia positive chemical ionization mode. Two
ion sets were measured: m/z 389, 390 and 400, corresponding
to the molecular ion and 257, 258 and 268, resulting from
fragmentation, for the analyses of DHN, [2H]DHN and internal
standard [2H11]DHN respectively. The MS source and quadru-
pole were set at 180 °C–126 °C and 300 °C–176 °C for the 2
ion sets respectively. The chromatograph temperature programwas: 170 °C for 1 min, increased by 10 °C/min up to 210 °C,
increased by 5 °C/min up to 280 °C and by 20 °C/min up to
320 °C for 10 min. Levels of HNE-proteins were calculated
over a minimum of duplicate injections.
2.5.3. DHN-MA assay
Levels of the conjugate, dihydroxynonane-mercapturic acid,
were determined in aliquots (400 μL) of 2h-urine samples when
available by enzyme immunoassay using polyclonal antibodies
as described by Gueraud et al. [37]. Concentrations were
calculated and expressed relative to the creatinine levels assayed
in the same urine samples.
2.6. Fatty acid analysis
Fasting free fatty acids were extracted from plasma
following the method previously described by Lepage et al.
[38] and analyzed by gas chromatography using nonadecanoic
acid (C19:1) as internal standard.
2.7. Calculations
BMI z-scores were calculated using the Epi Info software
from the Centers for Disease Control and Prevention (www.
cdc.gov/epiinfo/).
Peripheral insulin resistance was evaluated using the
Homeostasic Model Assessment [39] (HOMA) where
HOMA=([fasting BG (mM)]×[fasting insulin (pM)])/22.5.
Percentage of functional β-cells was estimated as calculated
by Tofe et al.:
β-cell (%)=[fasting insulin (pM)×3.33]/[fastingBG (mM)—
3.35] [40].
Mean Plasma Glucose was estimated using the equation
validated by Brennan et al.:
MPG=(1.47×A1c)— 1.15 [41].
2.8. Statistical analyses
Data are expressed as means±SE. Statistical differences were
assessed by factorial ANOVA, unpaired or paired Student's t-test
after verification of the normal value distribution of the popu-
lations. When variances were significantly different (F test),
Welch's correction was used. Correlation analyses were
performed with determination of the Pearson correlation
coefficient. Statistical significance was considered when pb0.05.
Note that theoretically, taking into account all the patients
(tested once and re-rested) should give a total of 47 sets of datawith
22 NGT, 18 IGT and 7 CFRD. However, for several parameters,
the data set was not always complete because of missing samples
(not available; i.e. pulmonary function, genotype).
3. Results
3.1. Metabolic parameters and pulmonary function
For the 31 patients (18 males), initial tests showed 16 (52%)
normal, 13 (42%) intolerant and 2 (6%) diabetic. Of the IGT
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were retested 6 to 24 months later. Twenty-two patients clas-
sified as NGT, 13 as IGT and 7 as CFRD at some point during
the study. We have analysed our data in different ways: (i)
taking into consideration the patients only tested once in com-
parison with those who have been retested and who changed in
terms of their glucose tolerance over time; (ii) taking into
account the evolution of patients with IGT (longitudinal
approach: 13 IGT but only 12 who have been retested, of
whom 6 became NGT, 5 became CFRD and 1 remained IGT),
(iii) taking into account only the patients who have been tested
once (16 NGT, 13 IGT and 2CFRD) in comparison with data
obtained from all tests performed. For all the parameters
considered in this study, there was no evidence of statistical
difference between patients tested once and those who changed
their glucose tolerance. Therefore, data are presented and
analysed taking into account all OGTT performed. Table 1
describes the patients' demographic, genetic and anthropo-
metric data according to glucose tolerance taking into account
the patients only tested once and all tests performed. Average
age of the whole population was 14.0±0.2 years. There was no
significant difference when taking into account only the patients
tested once vs including data from IGT patients who have been
retested. No significant difference was observed for age or BMI
z-score between females and males. Most patients wereTable 1
Demographic, genetic and anthropometric data and evaluation of glucose metabolis
NGT
M/F 9/7–13/9
Total (%) 16 (52)–22 (52)
Age (years; n) 13.9±0.6 (16)
14.0±0.5 (22)
Mutations ΔF508 (%, n)
Homozygous 50.0 (7)–52.6 (10)
Heterozygous 42.9 (6)–36.8 (7)
Other mutations 7.1 (1)–10.5 (2)
Not genotyped 12.5 (2)–13.6 (3)
BMI z-score −0.35±0.17 (16)(p=0.49 vs all)
−0.18±0.16 (22)
Glucose (mM, n)
0-h 5.0±0.1 (16)
5.0±0.1 (22)
2-h 6.0±0.2 (16)
5.9±0.2 (22)
Insulin (pM, n)
0-h 52±7 (15)
53±6 (21)
2-h 286±60 (16)
298±54 (21)
A1c (%, n) 5.47±0.10 (13)
5.54±0.08 (18)
Pancreatic function
HOMA (n) 11.6±1.6 (15)
11.9±1.3 (20)
β-cell (%, n) 122±18 (15)
127±16 (20)
Data are means±SE; n=number of tests performed. The percentages ofΔF508 mutat
using the HOMAmodel. NGT: Normal Glucose Tolerance; IGT: Impaired Glucose T
all OGTT performed whereas the others are obtained from the patients tested only on
using factorial ANOVA; dpb0.001 vs NGT using Student unpaired t-test.homozygous for the ΔF508 mutation. BMI z-score tended to
be lower in the intolerant and diabetic groups but without
statistical significance. Among the 12 retested IGT patients, 6
(50%) reverted to NGT, 1 (8%) remained IGT and 5 (42%)
progressed to CFRD.
Table 1 also presents OGTT results, A1c levels and
estimation of insulin resistance and functional β-cell mass.
Fasting BG values were comparable across all groups. The
groups differed significantly by their 2-h BG values ( pb0.001).
Fasting insulin levels were similar among the groups. The 2-h
insulin levels tended to be higher in intolerant and diabetic
groups compared to the NGT group and did reach significance
( pb0.05) in the diabetic group. A1c trended upwards from
normal to intolerant to diabetic status without statistical signi-
ficance. A similar trend was observed for the estimate of insulin
resistance with glucose tolerance but did not reach significance
nor did the functional β-cell mass (15 and 23% decrease with
IGT and CFRD respectively), suggesting no significant β-cell
loss. A recent study has shown a strong correlation between A1c
and mean plasma glucose in CFRD [41]. Using the authors'
equation, we observed a significant difference in mean plasma
glucose between NGT and IGT patients when considering only
the patients tested once: 6.78±0.10 (n=12), 7.15±0.12 (n=13)
and 7.52 (n=2) mM for NGT, IGT and CFRD patients
respectively ( pb0.05 using unpaired t-test) but also betweenm and pancreatic function
IGT CFRD
9/4–9/4 0/2–4/3
13 (42)–13 (31) 2 (6)–7 (17)
14.0±0.5 (13) 13.5 (2)
14.0±0.5 (13) 14.4±0.8 (7)
55.6 (5)–55.6 (5) – –100 (2)
33.3 (3)–33.3 (3) –
11.1 (1)–11.1 (1) –
30.8 (4)–30.8 (4) 100 (2)–71.4 (5)
−0.17±0.28 (13)(p= 0.46 vs all) −0.63 (2)
−0.47±0.28 (16) −0.57±0.39 (7)
4.9±0.1 (13) 5.1 (2)
4.9±0.1 (18) 4.9±0.2 (7)
9.2±0.2 (13)d 12.4 (2)
9.3±0.2 (18)b 12.5±0.5 (7)bc
53±11 (11) 31 (2)
47±8 (18) 41±7 (7)
479±89 (13)(p=0.07 vs NGT) 312 (2)
412±69 (18) 476±143 (7)a
5.65±0.08 (13) 5.90 (2)
5.65±0.08 (17) 5.86±0.10 (7)
12.1±2.5 (11) 7.8 (2)
10.6±1.8 (16) 9.2±1.8 (7)
116±20 (11) 68 (2)
109±14 (16) 98±13 (7)
ion were calculated from the genotyped patients. Insulin resistance was evaluated
olerance; CFRD: Cystic fibrosis-related diabetes. Data in bold are obtained from
ce (no re-testing of IGT patients). apb0.05; bpb0.001 vs NGT; cpb0.001 vs IGT
Fig. 1. Relationship between plasma 2h-insulin and glucose. Plasma 2h-insulin
concentrations were plotted in relation to plasma 2h-glucose levels. A: using the
data of the patients tested once and B: all OGTT performed. In both cases, the
analysis of the insulin-glucose correlation (r 2=0.10 and 0.09 for A and B
respectively, pb0.05) revealed two subgroups of patients: one with a significant
correlation (insulin≤270 pM; r 2=0.60 and 0.27; p=0.002 and 0.015 for A and
B respectively) and one without any significance (insulin N270 pM; r 2=0.10
and 0.07; p=0.20 and 0.21 for A and B respectively). The dotted lines represent
the 95% confidence interval.
Table 3
Blood glutathione levels in relation to glucose tolerance and gender
Total glutathione (μM) GSSG/total GSSG/GSH
Glucose tolerance
NGT (n) 637±36 (19) 4.7±0.9 (16) 5.0±1.0 (16)
IGT (n) 647±52 (12) 7.0±1.7 (12) 7.9±2.1 (12)
CFRD (n) 795±230 (4) 4.2±2.1 (3) 4.4±2.2 (3)
Gender
Males (n) 585±25 (20) 6.4±1.2 (18) 7.2±1.5 (18)
Females (n) 740±74 (14)⁎ 4.2±0.9 (13) 4.5±1.0 (13)
Data are means±SE; n=number of tests performed. Whole blood glutathione
levels (oxidized glutathione (GSSG), total glutathione) were measured and
reduced glutathione (GSH) calculated. NGT: Normal Glucose Tolerance; IGT:
Impaired Glucose Tolerance; CFRD: Cystic fibrosis-related diabetes. *pb0.05
vs males using unpaired t-test.
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performed: 6.96±0.11 (n=18), 7.15±0.12 (n=17) and 7.46±
0.14 mM (n=7) for NGT, IGT and CFRD patients respectively
( pb0.05 using factorial ANOVA).
A close analysis of the positive correlation between 2-h insulin
and glucose levels (r 2=0.09, pb0.05, not shown) outlined 2
subgroups of patients. In the first subgroup there was a strong
positive correlation between 2-h insulin and BG concentrationsTable 2
Pulmonary function in relation to glucose tolerance and gender
Predicted FEV1 (%) Predicted FEF25–75 (%)
Glucose tolerance
NGT (n) 89.3±3.7 (22) 69.5±6.2 (22)
IGT (n) 83.6±4.5 (16) 63.0±7.4 (16)
CFRD (n) 81.5±8.6 (6) 63.4±12.0 (6)
Gender
Males (n) 90.0±3.2 (30) 72.3±5.0 (30)
Females (n) 79.6±4.4 (15) 55.8±7.4 (15)
Data are means±SE; n=number of tests performed. Pulmonary function is
expressed as percentage predicted forced expiratory volume in one second: FEV1
and forced expiratory flow25–75: FEF25–75. NGT: Normal Glucose Tolerance; IGT:
Impaired Glucose Tolerance; CFRD: Cystic fibrosis-related diabetes.(insulin level ranging from 49 to 270 pM; r 2=0.60 and r 2=0.27,
pb0.05, for taking into account only the patients tested once or
the whole population, respectively), whereas this correlation
disappeared in the second subgroup (insulin level N270 pM;
r 2=0.10 or 0.07, ns, for taking into account only the patients
tested once or the whole population, respectively). Fig. 1 shows
the relationship between 2-h insulin and 2-h BG concentrations.
At 2 h after the glucose challenge, insulin and BG increased until
glucose reached 7.7 mM on average. Then insulin levels rose
further to maintain the same glucose concentrations. At that point,
the linear relationship between insulin and glucose levels
disappeared; more insulin had to be secreted to maintain similar
BGvalues. Furthermore, insulin levels were significantly higher in
females: at baseline: 60±9 (n=15) vs 40±3 pM (n=28, pb0.05
using unpaired t-test) and at 2-h: 529±87 (n=15) vs 293±41 pM
(n=31) for females and males respectively (pb0.01 using
unpaired t-test, n=number of tests for all OGTT performed).
Consequently, the evaluation of insulin resistance using the
HOMA model was significantly higher in females compared to
males: 14±2 (n=15) vs 9±1 (n=28; pb0.05) as well as the
evaluation of functional β-cell mass (135±18 (n=15) vs 98±8
(n=28) % for females and males respectively; pb0.05, n=num-
ber of tests for all OGTT performed). Females also tended to have
higher BMI z-score: −0.05±0.24 (n=15) and −0.39±0.17
(n=28) for females and males respectively.
Percent predicted FEV1 and FEF25–75 were slightly dimin-
ished with IGT and CFRD (8.9%; Table 2). Females tended to
have lower % predicted FEV1 (12% decrease compared to males;
p=0.060 using unpaired t-test) and % predicted FEF25–75 (23%
decrease compared to males; p=0.08 using unpaired t-test).
3.2. Lung inflammation and infection
In order to evaluate the status of patients for lung
inflammation and infection, colonization by PA in sputum
cultures was tested. When considering only the patients tested
once, 9 of the 16 NGT patients were PA positive (56%), 1 was
identified as scanty and 6 (37%) were PA negative; of the 13
IGT patients, 8 tested positive (62%) and 5 negative (38%)
whereas 1 of CFRD patients was identified PA positive and 1
scanty. Of the 12 retested IGT patients, 3 of the 6 patients who
Fig. 2. Concentrations of blood HNE-protein adducts with glucose tolerance.
HNE-protein levels were measured in whole blood of CF patients with normal
(NGT, white bars), impaired (IGT, hatched bars) and diabetic (CFRD, black
bars) glucose tolerance. Results are expressed as means±SE (n=number of
tests) when available at 2-h. Data were analyzed by ANOVA after a natural
logarithm transformation to meet homoscedasticity (Bartlett's chi squared) and
showed a significant difference: #: pb0.05 vs NGT.
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and 2 remained PA positive (no data for 1 patient) whereas 5 of
the patients who became CFRD were PA positive. Therefore,Fig. 3. 2h-blood glucose and levels of blood HNE-protein adducts and urine DHN-M
correlation (r 2=0.16, pb0.05, n=35 tests performed) between the 2h-BG and the lev
associated with oxidative stress. The analysis of the urine concentration of the conjug
n=24 samples measured). The dotted lines represent the 95% confidence interval. B: W
correlation between blood HNE-P and 2h-BG did not reach significance ( p=0.19) wh
DHN-MA (r 2=0.23, p=0.028).taking into consideration all the data, there is a trend for an
increase in PA positivity from NGT to CFRD: 52% (11 positive,
9 negative, 1 scanty and 1 NA), 72% (13 positive, 5 negative)
and 86% (6 positive, 1 scanty) and for the NGT, IGT and CFRD
groups respectively. There is no evidence of difference between
males and females for colonization by PA (data not shown).
3.3. Oxidative stress markers
3.3.1. Glutathione assay
Total, reduced and oxidized glutathione levels were not
significantly different between groups (Table 3). The analyses of
glutathione according to gender, regardless of glucose tolerance,
revealed a trend for amore reduced environment in females: redox
ratio=2 GSSG/(GSH+2GSSG) (9.7±2.1 (n=13) vs 13.8±3.0
(n=18)) with a significant increase in total glutathione levels:
GSH+GSSG (Table 3) and GSH levels: 740±74 (n=14) vs 585±
25 μM (n=20) for females and males respectively ( pb0.05,
n=number of measurements for all OGTT performed).
3.3.2. HNE-Protein adducts assay
HNE-P adduct levels increased significantly with abnormal
glucose tolerance (Fig. 2, 45% increase with IGT and 109% withA conjugates. A: Taking into consideration all OGTT performed, the positive
els of HNE-protein adducts suggests that 16% of the increase in glucose levels is
ate DHN-MAwith the 2h-BG revealed a negative correlation (r 2=0.23, pb0.05,
hen taking into account the data obtained only from the patients tested once, the
ereas it was very similar to what observed with the whole population for urinary
Fig. 4. Outcome of patients with Impaired Glucose Tolerance. IGT patients were retested 6 to 12 months later. The numbers in brackets indicate the male/female ratio.
Table 4
Blood levels of HNE-protein adducts with changes in glucose tolerance
following nutritional recommendations
Patient HNE-protein adducts (nM)
IGT NGT
#1 105.9 1.9
#2 66.7 2.5
#3 182.8 56.7
IGT CFRD
#4 66.7 163.5
#5 100.6 144.5
IGT IGT
#6 142.4 23.1
79.1
Whole blood HNE-protein levels (nM) were measured in some IGT patients
who received NR and repeated when they were retested for glucose tolerance.
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concentrations were expressed in pmol/mg protein (results not
shown). HNE-P levels correlated positively with 2h BG
concentrations (r2=0.16, pb0.05, Fig. 3A), attributing 16% of
the increase in glucose levels in CF patients to increased oxidative
stress. There was no correlation between HNE-P levels and
glutathione (reduced, oxidized or ratios). No significant change
was observed between male and female levels of blood HNE-
protein levels (97.6±15.8 (n=13) vs 88.2±10.4 nM (n=23) for
females and males respectively; n=number of tests performed).
3.3.3. DHN-MA assay
The HNE fraction bound to GSH was estimated with its
urinary end-product concentration, DHN-MA, measured in
urine samples of some patients (14 NGT, 11 IGT and 1 CFRD).
Urine concentrations of DHN-MA conjugate were significantly
decreased in IGT patients compared to NGT: 1.22±0.09 (n=11)
vs 1.83±0.23 (n=14) pg/μg creatinine ( pb0.05 using unpaired
t-test). These levels were not associated with measured blood
concentrations of HNE-P adducts but negatively correlated with
2h-BG concentrations (r 2 =0.23, pb0.05, Fig. 3A).
Of the 12 IGT patients retested, 3 did not receive NR (Fig. 4).
These patients remained IGT at 6 months and progressed to
CFRD at 12 months. Of the 9 patients who underwent NR, 2
progressed to CFRD (22%), 1 remained intolerant (22%) and 6
normalized (67%). Table 4 presents the HNE-protein levels in
some patients with NR. Three of the 6 IGT patients reverting to
NGT had their HNE-protein adduct levels repeated, showing a
significant drop (88%) once glucose metabolism normalized
( pb0.05, paired t-test), while levels increased (94%) in the 2
IGT patients with NR progressing to CFRD. The patient who
received NR and remained intolerant had an initial drop ofHNE-protein level of 84% and then 44% compared to the
original measurement. These observations were unaccompanied
by changes in BMI z-score, pulmonary function and glutathione
levels (data not shown).
3.4. Fatty acid profiles
Of the 31 patients enrolled in the study, samples from only 12
patients (8 NGT and 4 IGT) were available for determination of
plasma fatty acid profile. None of the IGT patients were re-
analyzed when retested for glucose tolerance. In general, total
fatty acid levels were 26% lower with IGT compared to NGT. As
presented in Table 5, saturated and monounsaturated fatty acids
were decreased in patients with impaired glucose tolerance
Table 5
Fatty acid profiles in CF patients with normal and impaired glucose tolerance
Fatty acids (n; male:female) NGT (8; 4:4) IGT (4; 3:1)
Saturated (SFA; mM) (% variation vs NGT)
C16:0 3.2±0.5 2.1±0.2 (33%)
C18:0 0.59±0.04 0.49±0.04 (17%)
Sum 4.3±0.6 2.9±0.3 (32%)
Monounsaturated (MUFA; mM) (% variation vs NGT)
C16:1n-7 0.44±0.08 0.28±0.06 (36%)
C18:1n-9 2.1±0.2 1.4±0.1 (31%)
SUM 2.9±0.3 2.0±0.2⁎ (31%)
Polyunsaturated (PUFA) (% variation vs NGT)
n-6 (mM)
C18:2n-6 2.2±0.2 2.0±0.2 (10%)
C20:4n-6 0.49±0.03 0.42±0.04 (14%)
n-3 (μM)
C18:3n-3 61.6±14.0 46.5±6.5 (25%)
C20:5n-3 55.3±10.2 41.3±8.8 (25%)
C22:6n-3 94.5±19.8 43.0±6.9⁎ (55%)
n-9 (μM)
C20:3n-9 20.4±3.7 14.6±5.5 (29%)
SUM (mM) 3.2±0.3 2.8±0.2 (13%)
Total (SFA-MUFA-PUFA; mM) 10.4±1.1 7.7±0.5 (26%)
Ratio (% variation vs NGT)
∑n-3/∑n-6 0.080±0.009 0.061±0.005 (25%)
C22:6n-3/Total 0.009±0.002 0.006±0.001 (35%)
C20:3n-9/C20:4n-6 0.043±0.009 0.034±0.013 (21%)
Plasma fatty acid profile was determined in some patients with normal (NGT)
and impaired (IGT) glucose tolerance. Data are means±SE; n=number of
patients analyzed. *pb0.05 vs NGT using unpaired t-test.
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reached significance only in the concentration of monounsatu-
rated fatty acids (sum of saturated+monounsaturated fatty acids:
32% decreased; p=0.055 using unpaired t-test). Compared to
NGT patients, levels of n-6 fatty acids as LA (C18:2n-6) and AA
(C20:4n-6) aswell as n-3 fatty acids were found to be decreased in
IGT patients. Nevertheless, the significance was observed for
DHA only (C22:6n-3; pb0.05). EFAD has been reported in CF
patients with pancreatic insufficiency. Its evaluation through the
ratio (C20:3n-9)/(C20:4n-6) showed no deficiency and no
significant difference between the two groups.
The levels of n-3 (C18:3n-3, C20:5n-3, C22:6n-3), n-6
(C18:2n-6) and total polyunsaturated fatty acids were signifi-
cantly increased in females (n=5) compared to males (n=7)
(104, 28 and 32% for n-3, n-6 and PUFA respectively; pb0.05,
unpaired t-test). Furthermore, the ratio n-3/n-6 was significantly
higher in females compared to males (59%, 0.094±0.001 (n=5)
vs 0.059±0.003 (n=7) for females and males respectively;
pb0.05). No gender difference was observed for EFAD.
4. Discussion
This study is the first involving a cohort of pediatric CF
patients investigating glucose metabolism and oxidative stress.
The ΔF508 mutation was the most common genotype in our
population as previously published [42]. We were unable to draw
conclusions regarding genotype and risk for abnormal glucosemetabolism given the small number of IGT and CFRD patients
genotyped.
Studies have shown that deterioration in pulmonary function,
weight loss, decreased BMI and increased need for pancreatic
enzymes precede CFRD [43]. However, a large Canadian study
(5.2% CFRD) showed no change in pulmonary function or
survival 5 years before and after diagnosis [44]. Our patients
with CFRD tended to have diminished pulmonary function and
lower BMI z-scores. However, these trends were subtle. This
may be explained by early diagnosis of abnormal glucose
metabolism in our cohort.
Normal fasting BG levels do not predict glucose tolerance in
CF patients (Table 1). This underscores the importance of
routine oral glucose tolerance testing in this population. A1c,
though trending upwards in IGT and CFRD groups, was not
significantly different and is not indicative of glucose
metabolism in CF as previously published [45]. However, the
evaluation of the mean plasma glucose using A1c values [41]
showed a significant difference between NGT and CFRD
patients. A1c may therefore be a useful tool for this estimation
in the follow-up of CF patients. This finding remains to be
confirmed in a larger cohort of pediatric patients.
Impaired insulin secretion has been demonstrated in CF and
may be secondary to β-cell dysfunction [46]. Reports of reduced
and increased insulin secretion in CFRD imply that both
insulinopenia and insulin resistance may be involved in abnormal
glucose metabolism [9,47]. We found no frank insulinopenia in
children with IGTor CFRD. In our patients, 2-h insulin correlated
positivelywith 2-h BG levels. Insulin levels increasedwithBGup
to a plateau after which significant levels of insulin were required
to maintain glucose concentration, suggesting a component of
insulin resistance (Fig. 1). Evaluation of insulin resistance did not
reveal any change but the HOMA model does not take into
account area under the curves of insulin secretion and/or BG. CF
patients may also present a decrease and/or delay in peak insulin
secretion [48]. Estimation of functional β-cell mass was not
significantly decreased (15%) in patients with CFRD. This may
be explained by the calculation method which relied solely on
fasting insulin and glucose levels. However, these data are not
compared to those found in a healthy pediatric population. Similar
observations have been recently reported on glucose tolerance
and insulin secretion in children [49].
Insulin levels in females were significantly higher. Studies
have suggested that females are intrinsically more insulin
resistant, possibly because of specific sex-linked gene expression
and differences inmetabolic controls, such as signaling pathways,
substrate shuttling and receptor function [50]. This is confirmed
by our observation with a significant higher average value of the
HOMA for females when compared to males. Furthermore,
insulin resistance increases with higher BMI z-score, and
percentage of body fat is greater in females [51,52].
Our female patients had a 23% decrease in % predicted
FEF25–75 compared to males regardless of glucose status. Re-
duced pulmonary function in CF female adults has been reported
[53], possibly due to reduced energy intake and higher resting
energy expenditure but also to genetic factors [54]. Studies have
shown that female CFRD patients have a poorer prognosis [55]
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is 20% lower compared to CF patients without CFRD [56].
However, females with newly diagnosed CFRD did not have
significant reduction in pulmonary function compared tomatched
controls. This suggests that early intervention in females with
CFRD may prevent worsening of pulmonary function. We were
unable to demonstrate a difference in pulmonary function in
females with CFRD versus those with NGT but numbers were
small (2 and 9 respectively). Also, patients were newly diagnosed
andmay not yet have shown a decline in pulmonary function [56].
Of the 4 retested female IGT patients, 3 became NGT and 1
CFRD. All showed an improvement in pulmonary function (data
not shown) over the study period.
Nutritional recommendations given to IGT patients appeared
to have a beneficial impact on progression to diabetes. CFRD is
preceded by a variable period of glucose intolerance [57]. Ours is
the first study to consider nutritional intervention as a means of
delaying progression to diabetes. However, given our small
numbers, the lack of objective measures of compliance to NR and
of meticulous evaluation of nutritional status, further studies
investigating the effects of nutritional intervention in patients with
glucose intolerance on the progression to CFRD are warranted.
CF is characterized by chronic inflammation, lung infection
and is associated with increased oxidative stress [10,11]. Our data
show a trend for an increase of PA colonization with impairment
of glucose tolerance but that remains to be confirmed in a larger
population of patients. Reduced antioxidant capacity in CF also
suggests a state of increased oxidative stress [11,58] due to
production and release of reactive oxygen and nitrogen species by
inflammatory processes [59] and/orCFTRdysfunction. Similarly,
diabetes has been associated with increased oxidative stress. The
formation of ROS consequent to hyperglycemia is likely
mediated through nonenzymatic glycation [60] and oxidation of
proteins [20] and molecular rearrangements with production of
more ROS [21] which can result in diminished antioxidant
capacity and activation of redox-sensitive transcription factors
[16]. The positive correlation between blood HNE-P and glucose
levels suggests that 16% of the increase in glucose levels in this
group of patients can be associated with an increase in HNE-P
concentrations related to increased oxidative stress.
Erythrocyte GSSG appeared to be greater in the IGT group
although a small decrease was observed in the CFRD group.
However, due to the small number of patients and the high
variability in the latter group, no conclusion can be drawn. Also,
there were no significant group differences in GSSG/GSH ratios.
As previously described in children [61], we observed a
difference in glutathione levels between males and females,
with significantly higher total glutathione levels, GSH levels and
a more reduced environment in females. This may be related to
different hormonal environments [62].
Under normal conditions, cells contain basal levels of HNE
(b1 µM), which may act as a signaling molecule [63]. Under
oxidative stress conditions, the increased HNE production can
lead to modifications of biological molecules and proteins [19].
We measured HNE-P adducts in whole blood to provide an
accurate assessment of ongoing oxidative stress in CF. CFRD
patients had increased (109%) HNE-P levels compared to NGTpatients, suggesting further oxidative stress with CFRD.
Exogenous HNE altered glucose-induced β-cell insulin secretion
in an animal model [64]. It is likely that such HNE processes have
not significantly modified β-cell function in newly diagnosed
patients given the absence of frank insulinopenia in our patients.
To the best of our knowledge, this study is the first to identify a
direct link between 2-h BG and oxidative stress evaluated by
HNE-P adducts. Moreover, in 3 patients, we measured similar
levels of HNE-P at fasting and 2-h post OGTT (data not shown).
This suggests that HNE-P may represent a long-term index of
oxidative stress associatedwith chronic hyperglycemia. However,
this remains to be further investigated. Differences observed in
glutathione levels between males and females may suggest that
females have better defence mechanisms against oxidative stress
(i.e. more GSH). However, concentrations of HNE-P did not
differ significantly between females and males.
DHN-MA is themajor urinarymetabolite ofHNE and presents
at physiological levels [23]. In conditions of induced oxidative
stress, increased levels of DHN-MA levels have been reported in
animals [24]. Although this metabolite originates from the
conjugation of HNE with GSH, no decrease in GSH levels was
observed in IGT patients. This may represent a GSH synthetic
response to ongoing oxidative stress, as represented by the
increasing HNE-P adduct concentrations in the IGT and CFRD
groups. NGT patients showed higher DHN-MA levels compared
to IGT whereas they presented lower concentrations of HNE-P
(Fig. 3). Assuming that the nutrition and intake of exogenous
HNE are similar across groups, we can raise two possibilities that
bridge these results. Firstly, one can speculate that the increased
HNE production is associated with a higher formation of
conjugates with GSH but the malfunction/absence of CFTR
could also affect the DHN-MA conjugates, decreasing their levels
in urine. Another possibility is that the HNE produced by n-6 FA
peroxidation is mainly diverted toward proteins as glutathione
imbalance may also affect HNE metabolism in CF. However, not
much is known about these metabolic pathways and they remain
to be investigated.
Notably, among the IGT patients retested, HNE-P levels
significantly decreased in those reverting to NGTwhereas levels
increased in patients who became diabetic. These results
confirm the link observed between BG and oxidative stress
evaluated by HNE-P adducts. It may be speculated that the
decrease in HNE-P levels in the IGT patient who remained
intolerant preceded an improvement in glucose tolerance. This
would support the hypothesis that changes in oxidative stress
precede disturbances in glucose metabolism.
Among the metabolic abnormalities in CF, disturbances in FA
profile were reported in children and adults [65]. However, a large
number of studies have characterized the FA composition in
different compartments (i.e. serum vs plasma vs erythrocyte
phospholipids) [66–68], using different methods (i.e. capillary
GC, GCMS) making comparisons and data interpretation
difficult. The most common observation concerns a decrease in
both the n-6 fatty acids [69,70] and DHA (C22:6n-3) [71].
Moreover, the severity of the perturbations has been related to
pancreatic status [30], genotype [72] and pulmonary functionwith
increased oxidative stress [32]. In our patients, fatty acid
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studies [69,73]. Moreover, using a recently validated tool that
could be an efficient diagnostic marker of CF [74], the product of
plasma levels of (C18:2n-6)×(C22:6n-3) revealed that all our
patients are within the expected range for CF (∼20: 18.4±3.2;
n=12 vs∼40 for healthy controls [74]) without significant change
with glucose tolerance. The absence of EFAD evaluated using the
ratio (C20:3n-9)/(C20:4n-6), is consistent with others reports
[30,75] and may be due to the fact that no pancreatic insufficiency
was reported in our patients. Not much information is available
related to FA and glucose metabolism in CF. Our results showed
significant decreases for the sum of monounsaturated fatty acids,
DHA and the ratio (sum FAn-3)/(sum FAn-6) with impairment of
glucose tolerance. However, further studies including diabetic CF
patients and controls are needed to confirm our findings.
HNE results from the lipid peroxidation of n-6 unsaturated
fatty acids and lipoprotein phospholipids [76,77]. Although IGT
patients exhibited an increase inHNE-P levels (43%) compared to
NGT patients, levels of n-6 fatty acids such as LA (C18:2n-6) and
AA (C20:4n-6) were found to be only slightly decreased (∼12%).
Notably, concentrations of HNE-P were measured in whole
blood, referring to a contribution of erythrocyte membrane status,
whereas fatty acid profile was analyzed in plasma. Since FA of the
n-3 and n-6 families are essentially structural components of
membrane phospholipids, analyses of the fatty acid composition
in erythrocyte membrane could be more appropriate to relate with
HNE-P levels and themajor lipids ongoing the peroxidation. Fatty
acids such as AA and the precursor of DHA, EPA (C20:5n-3), are
involved in the production of eicosanoids such as prostaglandins,
prostacyclins, thromboxanes and leukotrienes which affect
inflammation in CF. One can speculate that the observed decrease
in n-3 fatty acid levels with IGT may be explained by a
suppressive anti-inflammatory effect of n-3 on the increased
formation of proinflammatory products by n-6 fatty acids.
During the course of CF, it has been shown that female
patients were more prone to inflammation and had decreased
pulmonary function (percent predicted FEV1) compared to
males [53]. Increased levels of LA and decreased levels in major
n-3 fatty acids were found to be positively correlated with
pulmonary function in pre-adolescent CF children [78]. Con-
sistently, our female patients exhibited significantly lower levels
of n-3 FA compared to males, which could potentially be linked
to lower pulmonary function.
5. Conclusion
In summary, this study is the first showing a direct link
between blood levels of glucose and oxidative stress as evaluated
with blood levels of HNE-P in patients with CF. Previously
published methods for measuring HNE-protein adducts using
immunohistochemistry are mostly semi-quantitative. Further
documentation of the relationship between glutathione, HNE-
protein adducts and HNE metabolism in healthy controls and
diabetic patients is required. Our preliminary data regarding the
potential role of nutritional intervention for the prevention or
delay of CFRD in patients with IGT suggest the need for larger
clinical studies designed specifically for proper documentation ofdiet implementation and compliance, effect on growth and
clinical status, quality of life, as well as impact on the deve-
lopment of CFRD. Finally, our data on FA profile with glucose
intolerance suggest that inflammation and oxidative stress could
be related to the development of CFRD and mediated through
changes in lipid peroxidation.
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